Loading...
NPI 1821290669 · Honolulu, HI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Wihc, LLC is a clinical medical laboratory provider located in Honolulu, Hawaii. This profile covers 3 Medicare and 16 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Wihc, LLC |
| Address | 438 Hobron Ln Ste 315 |
| City | Honolulu |
| State | HI |
| ZIP | 96815 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 4, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $8.6M |
| Medicare | $72.5K |
WIHC, LLC is a Honolulu-based Clinical Medical Laboratory with an NPI enumerated on 2007-06-04 (~19 years ago). Its billed activity is heavily skewed toward Medicaid by scale, reporting Total Medicare revenue of $72.5K versus Total Medicaid revenue of $8.6M, indicating the provider is effectively Medicaid-centric in overall revenue.
The provider’s code mix is concentrated on drug testing services: the top Medicare and Medicaid revenue drivers are G0483 and G0482 (definitive GC/MS- or LC/MS-based drug identification across multiple drug classes) and 80307 (presumptive instrumented chemistry screening). This combination of high-complexity definitive testing (G0483/G0482) plus very large-volume presumptive screens (80307) implies a workflow that supports both high-throughput screening and confirmatory laboratory capabilities.
Medicare revenue is entirely concentrated in three codes — the top 3 Medicare codes account for 100.0% of its Medicare revenue — with G0483 representing 50.4%, G0482 26.9%, and 80307 22.7% of Medicare revenue. On these codes the provider’s national standing is modest: G0483 ranks #427 of 1063 (60th percentile), G0482 ranks #709 of 1618 (56th percentile), and 80307 ranks #1432 of 4760 (70th percentile), consistent with typical/unremarkable national volumes rather than national dominance.
Medicaid revenue is similarly concentrated: the top 3 Medicaid codes account for 94.5% of its Medicaid revenue, with G0483 at $4.1M (48.0%), 80307 at $2.4M (27.7%), and G0482 at $1.6M (18.8%). In-state competitiveness is strong for these lines — G0483 ranks #1 of 4 providers in-state (100th percentile), 80307 ranks #2 of 26 (96th percentile; notably above typical state volume), and G0482 ranks #2 of 4 (67th percentile) — indicating a leading regional position on definitive drug testing and a very large presence on presumptive screening.
Operational scale is evident in claim volumes reported on Medicaid for core tests: 35.7K claims for G0483 and 61.5K claims for 80307, with respective Medicaid revenues of $4.1M and $2.4M. Those magnitudes point to high-throughput, sustained Medicaid business that likely relies on state payer relationships and large institutional or programmatic ordering sources rather than sporadic outpatient testing.
The provider also bills a set of low-revenue infectious disease and molecular codes with negligible Medicaid revenue contribution (for example, U0003: 43 claims, $2.9K revenue; and multiple 27-claim entries with $162 revenue each such as 87651, 87541 and others). These small-volume NAAT and organism-specific tests appear ancillary to the core drug-testing business and are not material revenue drivers.
Because Medicaid dominates the revenue base ($8.6M vs $72.5K Medicare) and the top 3 Medicaid codes make up 94.5% of Medicaid revenue, the provider’s financial profile is highly sensitive to reimbursement and utilization shifts for G0483, 80307, and G0482. Contracting, rate changes, or utilization management by the state Medicaid program or major Medicaid payers would therefore have an outsized effect on WIHC’s overall revenue.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 150 | $240 | $36.5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 100 | $200 | $19.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 270 | $60 | $16.5K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 3 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 35,740 | $120 | $4.1M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 61,480 | $40 | $2.4M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16,920 | $100 | $1.6M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,280 | $50 | $237.4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,320 | $70 | $232.3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 40 | $70 | $2.9K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 30 | $10 | $200 |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 30 | $10 | $160 |
| 87541 | The lab analyst performs a test for the bacteria Legionella pneumophila using amplified nucleic acid probe technique. L. pneumophila can inhabit facility water and air conditioning systems and may… | 30 | $10 | $160 |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 30 | $10 | $160 |
Showing 1–10 of 16
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
16 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 9,340 | $100 | $1.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 10 | 3,320 | $70 | $1.3M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 10 | 9,110 | $90 | $996.4K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 16 | 20 | 1,060 | $60 | $547.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2 | 30 | 2,500 | $40 | $455.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 16 | 20 | 1,070 | $50 | $440.8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 17 | 20 | 600 | $50 | $345.9K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 5 | 10 | 70 | $920 | $281.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 20 | 720 | $40 | $165.7K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 5 | 10 | 430 | $40 | $103.9K |
Showing 1–10 of 16
Other providers in the same ZIP code as Wihc, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Waikiki Health | HI | Federally Qualified Health Center (FQHC) | $0 | $22.3M |
| Radford Y. Goto, Dmd, LLC | HI | Dental Clinic/Center | $0 | $1.5M |
| Hale Maka Ike LLC | HI | Optometrist | $0 | $920.6K |
| Kellen Kashiwa | HI | Optometrist | $784.8K | $0 |
| Phillip Duran | HI | Optometrist | $1.6K | $628.6K |
| Peter Hurlbut-miller | HI | Retina Specialist (Ophthalmology) Physician | $509.4K | $0 |
| Errol Hamarat | HI | Psychologist | $0 | $489.9K |
| Rebecca Beardsley | HI | Counseling Psychologist | $0 | $375.8K |
| Center For Sight - West Oahu LLC | HI | Ophthalmology Physician | $0 | $365.6K |
| Aaron Kaplan, Ph.d., Inc. | HI | Clinical Psychologist | $0 | $178.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.